- Home
- LNZA vs TCRX Comparison
LNZA vs TCRX Comparison
Compare LNZA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- TCRX
- Stock Information
- Founded
- LNZA 2005
- TCRX 2018
- Country
- LNZA United States
- TCRX United States
- Employees
- LNZA N/A
- TCRX N/A
- Industry
- LNZA Major Chemicals
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- TCRX Health Care
- Exchange
- LNZA Nasdaq
- TCRX Nasdaq
- Market Cap
- LNZA 98.1M
- TCRX 91.7M
- IPO Year
- LNZA N/A
- TCRX 2021
- Fundamental
- Price
- LNZA $0.40
- TCRX $1.77
- Analyst Decision
- LNZA Hold
- TCRX Strong Buy
- Analyst Count
- LNZA 2
- TCRX 6
- Target Price
- LNZA $2.00
- TCRX $9.50
- AVG Volume (30 Days)
- LNZA 2.6M
- TCRX 252.2K
- Earning Date
- LNZA 08-19-2025
- TCRX 08-12-2025
- Dividend Yield
- LNZA N/A
- TCRX N/A
- EPS Growth
- LNZA N/A
- TCRX N/A
- EPS
- LNZA N/A
- TCRX N/A
- Revenue
- LNZA $48,831,000.00
- TCRX $6,961,000.00
- Revenue This Year
- LNZA $18.90
- TCRX $159.20
- Revenue Next Year
- LNZA $47.56
- TCRX N/A
- P/E Ratio
- LNZA N/A
- TCRX N/A
- Revenue Growth
- LNZA N/A
- TCRX N/A
- 52 Week Low
- LNZA $0.14
- TCRX $1.02
- 52 Week High
- LNZA $2.74
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- LNZA 53.86
- TCRX 53.55
- Support Level
- LNZA $0.36
- TCRX $1.60
- Resistance Level
- LNZA $0.46
- TCRX $1.87
- Average True Range (ATR)
- LNZA 0.09
- TCRX 0.11
- MACD
- LNZA -0.01
- TCRX -0.02
- Stochastic Oscillator
- LNZA 21.55
- TCRX 43.59
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.